Advancing Combination Therapies with Amylin Analogs to Achieve Greater Weight Reduction for Improved Cardiometabolic Health
Time: 9:30 am
Details:
- Combining GLP-1 agonists with amylin analogs for enhanced satiety and glucose control to achieve greater weight reduction for improved cardiometabolic health
- Optimizing dosing ratios of co-administered peptides for synergistic appetite suppression to maximize weight loss efficacy for reduced caloric intake
- Evaluating long-term cardiovascular outcomes for comprehensive patient benefit to reduce cardiometabolic risk for enhanced overall health
